

ASX Release

21<sup>st</sup> December 2015

## EPICHEM AWARDED TWO YEAR CONTRACT EXTENSION FROM DNDi

PharmAust Limited (ASX: PAA) is pleased to announce that its wholly owned subsidiary, Epichem Pty Ltd, has been awarded a two year extension to its current contract with Drugs for Neglected Diseases *initiative* (DNDi).

The contract, which was due to finish on 31 December 2015, will now see Epichem continue to provide synthetic & medicinal chemistry support to DNDi's drug discovery projects until 31 December 2017. The extension will generate a further \$2.3M in revenues for Epichem during that period.

Epichem's Managing Director, Dr Wayne Best, said "Everyone in the company is delighted to have been given the opportunity to continue contributing to the important work undertaken by DNDi."

### About Epichem

Epichem is a wholly owned subsidiary of the ASX listed company PharmAust Limited. Located in Technology Park, Western Australia, Epichem has been delivering products and services in synthetic and medicinal chemistry to the global drug discovery and pharmaceutical industries in 33 countries worldwide for over 10 years. Epichem has a newly constructed state-of-the-art laboratory and has world class equipment and expertise in synthetic and medicinal chemistry for the cost effective synthesis of drug analogue libraries and intermediates. Epichem has considerable expertise and experience in multidisciplinary and multicentre drug discovery projects and is actively working with many clients and collaborators including the not-for-profit Drugs for Neglected Disease *initiative* (DNDi) as part of a consortium to find a cure for Chagas Disease. More information at [www.epichem.com.au](http://www.epichem.com.au).

### About DNDi

DNDi is a not-for-profit product development partnership working to research and develop new treatments for neglected diseases, in particular human African trypanosomiasis, leishmaniasis, Chagas disease, malaria, paediatric HIV, and specific helminth-related infections. DNDi was established in 2003 by the Oswaldo Cruz Foundation from Brazil, the Indian Council for Medical Research, the Kenya Medical Research Institute, the Ministry of Health of Malaysia, Pasteur Institute, and Médecins sans Frontières (MSF). WHO/TDR acts as a permanent observer. Since 2007, DNDi has delivered four treatments: two fixed-dose anti-malarials (ASAQ and ASMQ), NECT (nifurtimox-eflornithine combination therapy for sleeping sickness), and SSG&PM, a combination therapy to treat visceral leishmaniasis in Africa. For more information, [www.dndi.org](http://www.dndi.org).

For further details please contact:

Dr Wayne Best  
Managing Director  
Epichem Pty Ltd  
0421 545 820  
[www.epichem.com.au](http://www.epichem.com.au)